Latest news with #ABT
Yahoo
3 days ago
- Business
- Yahoo
Oversold Abbott Laboratories (ABT) Could Offer a Healthy Dividend Opportunity
Abbott Laboratories (NYSE:ABT) is included among the 10 Oversold Dividend Stocks to Buy According to Hedge Funds. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. The company reported strong earnings in the second quarter of 2025. It posted revenue of $11.1 billion, which showed a 7.37% growth on a YoY basis. The company reported GAAP diluted earnings per share of $1.01, while adjusted diluted EPS came in at $1.26. Gross margin was 52.7% of sales on a reported basis, with the adjusted gross margin reaching 57.0%, representing a 100 basis point improvement. Abbott Laboratories (NYSE:ABT) reiterated its guidance and pointed to strong momentum in both its devices and nutrition segments as it moves into the second half of the year. A brief valuation analysis, based on a five-year free cash flow CAGR of 5.74%— calculated using 6% growth in operating cash flow and 2% growth in capital expenditures— suggests that the current share price of $120.51 offers promising return potential. On June 13, Abbott Laboratories (NYSE:ABT) declared a quarterly dividend of $0.59 per share, which was in line with its previous dividend. This was the company's 406th consecutive quarterly dividend. In addition, ABT has raised its payouts for 53 years in a row. The stock offers a quarterly dividend of 1.86%, as of July 25. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Oversold Abbott Laboratories (ABT) Could Offer a Healthy Dividend Opportunity
Abbott Laboratories (NYSE:ABT) is included among the 10 Oversold Dividend Stocks to Buy According to Hedge Funds. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. The company reported strong earnings in the second quarter of 2025. It posted revenue of $11.1 billion, which showed a 7.37% growth on a YoY basis. The company reported GAAP diluted earnings per share of $1.01, while adjusted diluted EPS came in at $1.26. Gross margin was 52.7% of sales on a reported basis, with the adjusted gross margin reaching 57.0%, representing a 100 basis point improvement. Abbott Laboratories (NYSE:ABT) reiterated its guidance and pointed to strong momentum in both its devices and nutrition segments as it moves into the second half of the year. A brief valuation analysis, based on a five-year free cash flow CAGR of 5.74%— calculated using 6% growth in operating cash flow and 2% growth in capital expenditures— suggests that the current share price of $120.51 offers promising return potential. On June 13, Abbott Laboratories (NYSE:ABT) declared a quarterly dividend of $0.59 per share, which was in line with its previous dividend. This was the company's 406th consecutive quarterly dividend. In addition, ABT has raised its payouts for 53 years in a row. The stock offers a quarterly dividend of 1.86%, as of July 25. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Oversold Abbott Laboratories (ABT) Could Offer a Healthy Dividend Opportunity
Abbott Laboratories (NYSE:ABT) is included among the 10 Oversold Dividend Stocks to Buy According to Hedge Funds. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. The company reported strong earnings in the second quarter of 2025. It posted revenue of $11.1 billion, which showed a 7.37% growth on a YoY basis. The company reported GAAP diluted earnings per share of $1.01, while adjusted diluted EPS came in at $1.26. Gross margin was 52.7% of sales on a reported basis, with the adjusted gross margin reaching 57.0%, representing a 100 basis point improvement. Abbott Laboratories (NYSE:ABT) reiterated its guidance and pointed to strong momentum in both its devices and nutrition segments as it moves into the second half of the year. A brief valuation analysis, based on a five-year free cash flow CAGR of 5.74%— calculated using 6% growth in operating cash flow and 2% growth in capital expenditures— suggests that the current share price of $120.51 offers promising return potential. On June 13, Abbott Laboratories (NYSE:ABT) declared a quarterly dividend of $0.59 per share, which was in line with its previous dividend. This was the company's 406th consecutive quarterly dividend. In addition, ABT has raised its payouts for 53 years in a row. The stock offers a quarterly dividend of 1.86%, as of July 25. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
Yahoo
6 days ago
- Business
- Yahoo
Jim Cramer Says He 'Was Discouraged to Get a Mixed Update from Abbott Labs'
Abbott Laboratories (NYSE:ABT) is one of the stocks that Jim Cramer shed light on. Commenting on the company's recent earnings report results, Cramer said: 'Today, in an otherwise positive market, I was discouraged to get a mixed update from Abbott Labs, medical technology company that we've long owned for the Charitable Trust… I'd say two decades. When Abbott Labs reported this morning, the… results were perfectly solid. Management tightened their full-year earnings guidance rather than raising it while also taking down their organic sales growth forecast and their operating margin outlook. wavebreakmedia/ Abbott (NYSE:ABT) is a healthcare company engaged in the research, development, manufacture, and marketing of a wide range of medical products. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
21-07-2025
- Business
- Globe and Mail
Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield
If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company's management, portfolio, cash flow, capital return, and pipeline are why. The stock price came under pressure in July because the Q3 guidance update wasn't better than what the market expected. Sound crazy, but it's true: the robust outlook wasn't enough to keep speculators interested, but it isn't the speculators that matter in the long term. What matters in the long term is that the company's growth trajectory is positive, supporting a robust capital outlook that includes dividends and share repurchases. The combination of business growth, dividend distribution growth, and share repurchases serves as a lever for shareholder value that will propel the stock price to new highs. And the capital return is significant. The dividend is worth approximately 1.8% as of mid-July, is less than 50% of the earnings outlook, and has grown at a robust 10% CAGR over the past few years. Those are robust metrics for a Dividend Aristocrat, especially for a Dividend King like Abbott, which has increased its payout for over 50 years. That is a testament to management's foresight and execution, qualities that will continue to benefit investors in the long term. Abbott's share repurchases are also significant, as they reduce the share count quarterly. The company reduced its share count incrementally in the first half of the year and is expected to continue reducing it through the end of the year. Abbott Punished for Good Results, Solid Guidance Abbott Laboratories had a solid quarter, with revenue growth topping 7.4%, reported, about 70 basis points better than expected, driven by strength in all regions and reporting segments. Organically, growth was reported at 6.9% and 7.5% excluding COVID-19 testing supplies. Regionally, the U.S. was strongest at 8.7%, but the International Market was also solid at 6.6%. Segmentally, Diagnostics was the only weak point but was impacted by COVID, declining on a reported basis but rising incrementally organically. Other segments grew by at least 3%, led by a strong, industry-leading 12% gain in Medical Devices. The margin news is also good. Revenue leverage and operational quality offset macroeconomic pressures, resulting in a 100-basis-point improvement in adjusted gross and operating margins. The net result is $1.26 in adjusted earnings, only as expected, but up a leveraged 10.5% compared to the slower 7.4% top-line growth. The critical takeaway is that the cash flow is sufficient to sustain the capital return outlook, balance sheet health, and pipeline advancement, which support the stock price action over time. Regarding the pipeline, the company reported advancement of several key studies and one major approval for the quarter. Guidance is the sticking point for market action in July. The company narrowed its revenue growth range, indicating solid growth of 7.5% to 8%, with earnings in line with the consensus figure. However, a stronger catalyst was needed to lift the share prices. Investors should focus on growth, earnings, cash flow, and the pipeline, which promises to sustain them all. Analysts' Trends Provide Support for Abbott Laboratories in 2025 The analysts' trends are supportive of Abbott's stock price. The group issued a steady string of upgrades and price target revisions up to the day of the release, resulting in increasing coverage, firming sentiment, and a rising consensus price target. The group has the stock pegged at Moderate Buy with a bullish bias, forecasting a 10% increase relative to the pre-release closing price. That is sufficient to put this market at a new all-time high when reached. Where Should You Invest $1,000 Right Now? Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list. They believe these five stocks are the five best companies for investors to buy now...
